Abstracts Archive - Page 1245 of 2607 - ACR Meeting Abstracts

Abstract Number: 880 • 2018 ACR/ARHP Annual Meeting
Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
Bryant R. England¹, Harlan Sayles², Punyasha Roul², Apar Ganti³, Jeremy Sokolove⁴, William H. Robinson⁵, Grant W. Cannon⁶, Brian Sauer⁷, Joshua Baker⁸, Geoffrey M. Thiele² and Ted R. Mikuls⁹, ¹Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁵Stanford University, Palo Alto, CA, ⁶Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁷Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁸Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁹VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The immune system plays a critical protective role in cancer (CA) development. Perturbations in immune signaling, including cytokine dysregulation, may disrupt this homeostatic balance.…
Abstract Number: 881 • 2018 ACR/ARHP Annual Meeting
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
Sharon Dowell¹, Rodolfo Perez-Alamino², Christopher J. Swearingen³, Gail S. Kerr⁴ and Yusuf Yazici⁵, ¹Internal Medicine, Howard University, Washington, DC, ²Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Racial/ethnic disparities in comorbidity (CM) in rheumatoid arthritis (RA) may confound treatment and outcomes. Rheumatic Disease Comorbidity Index (RDCI) is a validated tool predicting…
Abstract Number: 882 • 2018 ACR/ARHP Annual Meeting
Predictors of Chronic Kidney Disease in US Veterans with Rheumatoid Arthritis
J. Steuart Richards¹, Richard Amdur², Grant W. Cannon³ and Gail S. Kerr⁴, ¹Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, ²Lead Biostatistician, Medical Faculty Associates Clinical Professor, Dept. of Surgery, George Washington University School of Medicine & Health Sciences, Washington, DC, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC
Background/Purpose: Chronic kidney disease (CKD) is a comorbidity that may affect patients with rheumatoid arthritis (RA). CKD restricts the use of disease modifying anti-rheumatic drugs…
Abstract Number: 883 • 2018 ACR/ARHP Annual Meeting
Evaluation of Fracture Risk and Osteoporosis in Males with Rheumatoid Arthritis
Kanchana Herath¹, Melissa Saul², Lei Zhu³ and Larry W. Moreland³, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Osteoporosis is an asymptomatic disease complicated by fractures and is associated with increased morbidity and mortality. Rheumatoid arthritis (RA) has been found to be…
Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks¹, Tracy Doyle², Jie Huang¹, Beatrice Pan², Elaine Fletcher², Ritu Gill³, Hiroto Hatabu², Mizuki Nishino⁴, David Murphy², Taysir Mahmoud², Christine K Iannaccone⁵, Michelle Frits², Bing Lu⁶, Ivan O. Rosas⁷, Paul Dellaripa², Michael E Weinblatt⁵, Elizabeth Karlson⁶ and Nancy A. Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Beth-Israel Deaconess Medical Center, Boston, MA, ⁴Dana-Farber Cancer Institute, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁷BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
Abstract Number: 885 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis¹, Fenglong Xie¹, Sasha Bernatsky², Shuo Yang¹, Lang Chen¹, Huifeng Yun¹ and Kevin Winthrop³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Oregon Health and Science University, Portland, OR
Background/Purpose: An increased incidence of herpes zoster (HZ) has been observed with Janus kinase inhibitors such as tofacitinib (TOF). However, among TOF users, a potentially…
Abstract Number: 886 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
Michael E Weinblatt¹, Peter C. Taylor², Edward C. Keystone³, Robert A. Ortmann⁴, Maher Issa⁴, Li Xie⁴, Stephanie de Bono⁴ and Yoshiya Tanaka⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries, including…
Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Yoshiya Tanaka¹, Tsutomu Takeuchi², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Yeong Wook Song⁶, Yi-Hsing Chen⁷, Mitsuhiro Rokuda⁸, Hiroyuki Izutsu⁸, Satoshi Ushijima⁸, Yuichiro Kaneko⁸, Teruaki Shiomi⁸ and Emi Yamada⁸, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁷Taichung Veterans General Hospital, Taichung City, Taiwan, ⁸Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Tsutomu Takeuchi¹, Yoshiya Tanaka², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Mitsuhiro Rokuda⁶, Hiroyuki Izutsu⁶, Satoshi Ushijima⁶, Yuichiro Kaneko⁶, Teruaki Shiomi⁶ and Emi Yamada⁶, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
Abstract Number: 889 • 2018 ACR/ARHP Annual Meeting
Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Josef S. Smolen¹, Stanley Cohen², Paul Emery³, William F C Rigby⁴, Yoshiya Tanaka⁵, Ying Zhang⁶, Alan Friedman⁶, Ahmed A. Othman⁶, Heidi S. Camp⁶ and Aileen L. Pangan⁶, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Metroplex Clinical Research Center, Dallas, TX, ³Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, United Kingdom, ⁴Dartmouth College, Hanover, NH, ⁵Univ of Occupational and Environmental Health, Kitakyushu, Japan, ⁶AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing…
Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Roy Fleischmann¹, Aileen L. Pangan², Eduardo Mysler³, Louis Bessette⁴, Charles Peterfy⁵, Patrick Durez⁶, Andrew Ostor⁷, Yihan Li², Yijie Zhou², Ahmed A. Othman², In-Ho Song⁸ and Mark C. Genovese⁹, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³Organización Medica de Investigación, Buenos Aires, Argentina, ⁴Laval University, Québec, QC, Canada, ⁵Spire Sciences LLC, Boca Raton, FL, ⁶Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁷Cabrini Medical Center, Malvern, Australia, ⁸AbbVie, Inc., north chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA
Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Aileen L. Pangan³, Alan Friedman³, Mohamed-Eslam Mohamed⁴, Su Chen⁴, Maureen Rischmueller⁵, Ricardo Blanco⁶, Ricardo M. Xavier⁷ and Vibeke Strand⁸, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., North chicago, IL, ⁵The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…
Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting
Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Nicolas Richard¹, Nigil Haroon², George Tomlinson³, Ismail Sari¹, Zahi Touma⁴ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
Abstract Number: 893 • 2018 ACR/ARHP Annual Meeting
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
Rebecca S. Overbury¹, Shaobo Pei², Gopi Penmetsa², Grant W. Cannon², Daniel O. Clegg³, Brian Sauer⁴ and Jessica Walsh⁵, ¹Internal Medicine, Divison of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT
Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing…
Abstract Number: 894 • 2018 ACR/ARHP Annual Meeting
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Sara Alehashemi¹ and Michael Ward², ¹Rheumatology, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, USA, Bethesda, MD
Background/Purpose: Few studies have examined risk of cancer in ankylosing spondylitis (AS) since the end of the radiation therapy era. With greater use of biologics,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].